利用树突细胞:在髓瘤中持续免疫控制的下一个前沿
1Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.
概括
在骨髓瘤患者中注射的树突细胞 (DC) 诱导了免疫反应. 这项研究支持在未来的组合疗法中使用DC来增强抗瘤免疫力并改善患者的治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症治疗 癌症治疗
背景情况:
- 基于免疫的疗法,包括T细胞重定向,已经显著推进了髓瘤治疗.
- 树突细胞 (DCs) 是重要的抗原呈现细胞,可以启动抗瘤免疫反应.
研究的目的:
- 研究树突细胞 (DC) 注射在诱导多发性骨髓瘤患者免疫反应中的潜力.
- 在骨髓瘤治疗的背景下,探索DCs在增强瘤免疫力的作用.
主要方法:
- 多发性骨髓瘤患者用树突细胞 (DC) 接种疫苗.
- 在DC疫苗接种后,监测和分析了免疫反应.
主要成果:
- 树突细胞 (DC) 注射成功诱导免疫反应在接种疫苗的骨髓瘤患者.
- 这些发现表明,在这个队列中,基于DC的疫苗接种具有免疫性.
结论:
- 树突细胞 (DC) 疫苗接种是刺激抗髓瘤免疫力的可行策略.
- 这些研究为开发涉及DCs的组合策略提供了基础,以改善髓瘤治疗结果.
更多相关视频
04:29Economical and Efficient Protocol for Isolating and Culturing Bone Marrow-derived Dendritic Cells from Mice
Published on: July 1, 2022
9.1K
11:48Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
11.5K
相关概念视频
01:31Hybridoma Technology
14.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.9K
01:27Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551